# Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance

> **NCT05933863** · — · COMPLETED · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 168 (actual)

## Conditions studied

- SCLC,Extensive Stage

## Interventions

- **DRUG:** PD-(L)1 antibody immunotherapy

## Key facts

- **NCT ID:** NCT05933863
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-29
- **Primary completion:** 2024-07-18
- **Final completion:** 2024-12-01
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05933863

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05933863, "Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05933863. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*